SCHEMBL6643385

SCHEMBL6643385

NC(=O)C1(c2c(-c3c(F)cccc3Cl)noc2N2CCCC2)CCCC(CNC(=O)c2ccccc2)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.38
ABCC1 P33527 2/20 0.38
NR1H4 Q96RI1 5/20 0.37
IL1B P01584 3/20 0.36
P2RX7 Q99572 3/20 0.36
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC9 Q9UKV0 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6638143 0.89 ALDH1A1 (0.43) KMT2AMEN1ALDH1A1LMNAABCC1
SCHEMBL6639035 0.85 ALDH1A1 (0.42) KMT2AMEN1ALDH1A1LMNAABCC1
SCHEMBL6642467 0.85 ALDH1A1 (0.41) KMT2AMEN1ALDH1A1LMNAABCC1
SCHEMBL6641231 0.81 ALDH1A1 (0.40) KMT2AMEN1ALDH1A1LMNAABCC1
SCHEMBL6802163 0.78 KMT2A (0.43) KMT2AMEN1ALDH1A1LMNAABCC1
SCHEMBL6644865 0.73 IL1B (0.33) KMT2AMEN1ALDH1A1ABCC1IL1B
SCHEMBL6639968 0.73 POLB (0.44) KMT2AMEN1ALDH1A1LMNASMN1; SMN2
SCHEMBL6638292 0.73 KMT2A (0.46) KMT2AMEN1ALDH1A1LMNASMN1; SMN2
SCHEMBL6639582 0.72 KMT2A (0.46) KMT2AMEN1ALDH1A1LMNASMN1; SMN2
SCHEMBL6834373 0.69 ABCC1 (0.34) KMT2AMEN1ALDH1A1LMNAABCC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1250340-B1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 LILLY CO ELI (US) 2004-11-17 EP disclosed
US-6743794-B2 MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE ELI LILLY AND COMPANY 2004-06-01 US disclosed
US-20030100576-A1 Methods and compounds for inhibiting mrp1 ELI LILLY AND COMPANY 2003-05-29 US disclosed
EP-1250340-A1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2002-10-23 EP disclosed
WO-2001046199-A1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100576-A1 Methods and compounds for inhibiting mrp1 ABCC1, ABCB11, ABCB1 KMT2A 4622/4885MEN1 3042/4885ALDH1A1 264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.